[The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
The tumour markers CA 19.9, CA 50 and CEA were measured preoperatively in 178 patients with symptoms of the upper abdomen and in 30 healthy individuals. Raising the cutoff of CA 19.9 and CA 50 and combining the three markers resulted in a sensitivity of 81.5% and a specificity of 86.7%. With increasing local tumour size and tumour spread, a non-significant tendency to greater tumour marker concentrations was observed. The tumour markers tested proved of great value in differentiating between pancreatic cancer and chronic pancreatitis. Sensitivity and specificity in this context were 81.5% and 100% respectively. In postoperative follow-up and in evaluation of new therapy regimens we recommend CA 19.9 as the marker most closely related to tumour progression or recurrence.
Röthlin
M
M
Departement Chirurgie, Universitätsspital Zürich.
Metzger
U
U
Joller
H
H
Largiadèr
F
F
D000230:Adenocarcinoma / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate; D002779:Cholestasis / Q000175:diagnosis; D002908:Chronic Disease; D003937:Diagnosis, Differential; D000939:Epitopes / Q000032:analysis; D006801:Humans; D009361:Neoplasm Invasiveness; D010190:Pancreatic Neoplasms / Q000276:immunology*; D010195:Pancreatitis / Q000276:immunology*
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate; D000939:Epitopes
Die Tumormarker CA 19.9, CA 50 und CEA in der Differentialdiagnose des Pankreaskarzinoms.